Pediatric Cancer

The University of Arizona Department of Pediatrics is the University of Arizona Cancer Center's clinical partner in treating children with cancer and blood disorders. 

The Division of Pediatric Hematology/Oncology/BMT has an outstanding tradition of providing excellence in patient care and research. The program is renowned in the Southwest for its clinical expertise in pediatric hematology-oncology and hematopoietic cell transplantation, providing state-of-the-art diagnosis and treatment and long-term management of patients with pediatric hematologic and oncologic diseases.

  • Evaluation, and comprehensive, compassionate care of children, adolescents and young adults with cancer
  • Matched related, haploidentical and unrelated hematopoietic cell transplantation, umbilical cord blood transplantation and autologous peripheral blood cell transplantation
  • Immunotherapy including CAR-T cell therapy and targeted antibody therapies 
  • Phase I/II/III clinical trials including many collaborative trials with the Children’s Oncology Group (COG) 
  • Targeted genetic testing to guide diagnosis and treatment 
  • Management of patients with post-solid organ transplant lymphoproliferative disorders
  • Consultation services for anemias, neutropenias and thrombocytopenias
  • Program to support adolescents and young adults with cancer 
  • Management of patients with sickle cell disease and other hemoglobinopathies
  • Comprehensive care of patients with hemophilia and other bleeding and clotting disorders
  • Our Childhood Cancer Survivor Clinic uses the Passport for Care to provide an individualized summary of cancer treatment, and a follow-up care plan with screening guidelines, and personal health recommendations based on the Children’s Oncology Group Long Term Follow-up Guidelines.

The mission of the Division of Pediatric Hematology/Oncology/BMT is to provide the highest quality of care and support for children with cancer and blood disorders and to promote acquisition of knowledge that will lead to improvement in therapy and cures.

Featured Clinical Trials

NCICOG Pediatric MATCH molecular analysis for therapy choice

ARST1431 A Randomized Phase 3 Study of Vincristine Dactinomycin Cyclophosphamide Alternating with Vincristine and Irinotecan Versus VACVI Plus Temsirolimus in Patients with Intermediate Risk Rhabdomyosarcoma

A Phase IIb Study of Haploidentical Bone Marrow Transplant with PostTransplant Cyclophosphamide andor Bendamustine TEST

Pediatric Oncology
Pediatric Oncology
Pediatric Oncology
Emmanuel Katsanis, MD
Pediatric Oncology
Pediatric Oncology
Baldassarre Stea, MD, PhD
Radiation Oncology


Clinical Research Coordination

Octavio Castanos

Research Data Coordination

Baker Fouad

Regulatory Coordination

Jessica Younts